Intratumoral Hemorrhage Induced by Atezolizumab plus Bevacizumab Combination Therapy in Patients with Hepatocellular Carcinoma
Oncology · 28.04.2026 · 1-10
DOI: 10.1159/000551878 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology, online erschienen am 28.04.2026. Verfasst von Takashi Takeuchi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Chiba University Hospital, Chiba, Japan. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Bevacizumab, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 11 Literaturangaben.
Abstract (Originalsprache)
Introduction
The purpose of this study was to investigate the incidence, risk factors, and prognostic significance of intratumoral hemorrhage (ITH) in patients with hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (A + B) therapy.
Methods
In this single-center retrospective cohort, 107 consecutive patients with HCC received A + B between October 2020 and March 2022 and underwent contrast-enhanced CT before and after therapy initiation. ITH was defined on the arterial phase of the first follow-up CT as intratumoral contrast pooling with a surrounding low-attenuation rim absent on non-contrast images. When present, foci were counted and graded (1–4); maximum tumor diameter was measured on portal-venous-phase images. Progression-free survival (PFS) from treatment start to progression or death was analyzed per RECIST 1.1 and modified RECIST (mRECIST).
Results
On the first follow-up CT, ITH was observed in 12 of 107 patients (11.2%). Patients with ITH had larger tumors than those without (p = 0.002). ITH was confined to the tumor; no intraperitoneal hemorrhage occurred. Among 9 patients with serial CTs, ITH grade decreased during follow-up in seven (77.8%). Thereafter, A + B was discontinued for progressive disease in five of these cases. PFS did not differ between patients with and without ITH by RECIST 1.1 or mRECIST (p = 0.74 and 0.98, respectively).
Conclusion
ITH was an early, on-treatment radiologic finding during A + B therapy for HCC and was more frequent in larger tumors. In this cohort, ITH was not associated with a statistically significant difference in PFS. Among patients with serial CT examinations, ITH grade decreased during follow-up in most evaluable cases; however, the clinical significance of this temporal change remains to be determined. No hemoperitoneum was observed, supporting careful observation in the absence of overt hemorrhage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Chiba University Hospital, Chiba, Japan.
- Diagnostic Radiology and Radiation Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan, hjmykt@chiba-u.jp.
- Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
- Diagnostic Radiology and Radiation Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Zitieren
APA
Takeuchi, T., Yokota, H., Koizumi, J., Takada, A., Miyakoshi, M., Ogasawara, S., Kanogawa, N., Inoue, M., Koroki, K., Yumita, S., Horikoshi, T., Nasu, K., & Uno, T. (2026). Intratumoral Hemorrhage Induced by Atezolizumab plus Bevacizumab Combination Therapy in Patients with Hepatocellular Carcinoma. Oncology, 1-10. https://doi.org/10.1159/000551878
Vancouver
Takeuchi T, Yokota H, Koizumi J, Takada A, Miyakoshi M, Ogasawara S, et al. Intratumoral Hemorrhage Induced by Atezolizumab plus Bevacizumab Combination Therapy in Patients with Hepatocellular Carcinoma. Oncology. 2026:1-10. doi:10.1159/000551878
BibTeX
@article{Takeuchi2026,
author = {Takeuchi, Takashi and Yokota, Hajime and Koizumi, Jun and Takada, Akiyo and Miyakoshi, Maaya and Ogasawara, Sadahisa and Kanogawa, Naoya and Inoue, Masanori and Koroki, Keisuke and Yumita, Sae and Horikoshi, Takuro and Nasu, Katsuhiro and Uno, Takashi},
title = {Intratumoral Hemorrhage Induced by Atezolizumab plus Bevacizumab Combination Therapy in Patients with Hepatocellular Carcinoma},
journal = {Oncology},
year = {2026},
pages = {1--10},
doi = {10.1159/000551878}
}
EUVIMED